EA200701434A1 - Тауриновый синтез, производство и применение в качестве лекарственного средства - Google Patents

Тауриновый синтез, производство и применение в качестве лекарственного средства

Info

Publication number
EA200701434A1
EA200701434A1 EA200701434A EA200701434A EA200701434A1 EA 200701434 A1 EA200701434 A1 EA 200701434A1 EA 200701434 A EA200701434 A EA 200701434A EA 200701434 A EA200701434 A EA 200701434A EA 200701434 A1 EA200701434 A1 EA 200701434A1
Authority
EA
Eurasian Patent Office
Prior art keywords
taurine
hyperlipidemia
medicine
manufacture
add
Prior art date
Application number
EA200701434A
Other languages
English (en)
Inventor
Магд Ахмед Котб Абдалла
Original Assignee
Магд Ахмед Котб Абдалла
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Магд Ахмед Котб Абдалла filed Critical Магд Ахмед Котб Абдалла
Publication of EA200701434A1 publication Critical patent/EA200701434A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Гиперлипидемия управляется антилипидемическими агентами, такими как секвестранты желчной кислоты, фибраты, ингибиторы HMG СоА редуктазы, приозводные никотиновой кислоты, гормоны щитовидной железы, количественно не учитывая наиболее важный метаболический путь для выведения холестерина у млекопитающих посредством формирования желчных солей, таких как соединения глицина или таурина. Данная заявка описывает применение таурина для управления гиперлипидемией. Таурин обеспечивают как таурин в дозе 10-30 мг/кг/день, чтобы усилить его конъюгацию к липидам крови, добавляют витамин В6 (пиридоксин) и поддерживают уровень крови и/или и добавляют предшественник цистеина или ацетилцистеина к водорастворимым витаминам. Комбинация является безопасной, эффективной и не проявляет эффекта привыкания.
EA200701434A 2005-01-05 2005-12-31 Тауриновый синтез, производство и применение в качестве лекарственного средства EA200701434A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
PCT/EG2005/000044 WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Publications (1)

Publication Number Publication Date
EA200701434A1 true EA200701434A1 (ru) 2008-10-30

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701434A EA200701434A1 (ru) 2005-01-05 2005-12-31 Тауриновый синтез, производство и применение в качестве лекарственного средства

Country Status (15)

Country Link
EP (1) EP1844006A2 (ru)
JP (1) JP2008526789A (ru)
KR (1) KR20070091198A (ru)
CN (1) CN101146767A (ru)
AP (1) AP2007004084A0 (ru)
AU (1) AU2005324199A1 (ru)
BR (1) BRPI0519606A2 (ru)
CA (1) CA2593563A1 (ru)
EA (1) EA200701434A1 (ru)
IL (1) IL184221A0 (ru)
MA (1) MA29238B1 (ru)
MX (1) MX2007008196A (ru)
NO (1) NO20074937A (ru)
TN (1) TNSN07226A1 (ru)
WO (1) WO2006072259A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091219A (ko) 2007-11-30 2010-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 시스테아민 산물을 이용한 비-알코올성 지방성간염(ｎａｓｈ) 치료 방법
CN103382170B (zh) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 一种牛磺酸的制备方法
CN106728405A (zh) * 2016-11-15 2017-05-31 陈思文 一种牛磺酸和水溶性茶多酚复方组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (ja) * 1981-12-22 1983-08-19 Junichi Azuma 心不全治療剤
JPH08208464A (ja) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd 高脂血症の治療及び予防薬
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (zh) * 2000-06-30 2002-03-20 张永春 牛磺酸合锌的生产工艺
CN1268733C (zh) * 2004-07-20 2006-08-09 刘辉 牛磺酸功能啤酒及其生产工艺

Also Published As

Publication number Publication date
TNSN07226A1 (en) 2008-11-21
MX2007008196A (es) 2008-02-22
JP2008526789A (ja) 2008-07-24
EP1844006A2 (en) 2007-10-17
NO20074937A (no) 2007-09-28
CA2593563A1 (en) 2006-07-13
WO2006072259A2 (en) 2006-07-13
AP2007004084A0 (en) 2007-08-31
AU2005324199A1 (en) 2006-07-13
KR20070091198A (ko) 2007-09-07
WO2006072259A3 (en) 2007-10-04
MA29238B1 (fr) 2008-02-01
CN101146767A (zh) 2008-03-19
IL184221A0 (en) 2008-12-29
BRPI0519606A2 (pt) 2009-02-25

Similar Documents

Publication Publication Date Title
BRPI0613754B8 (pt) compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
EA200401136A1 (ru) Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
MX2010002675A (es) Profarmacos para analogos de hormonas tiroideas.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201070572A1 (ru) Модуляция транспорта белков
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
TW200637839A (en) 1-thio-d-glucitol derivatives
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
MY151295A (en) Pyrimidyl indoline compound
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NZ600390A (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
MY155658A (en) A-isopropylphenyl glucitol compounds as sglti inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
DK1750703T3 (da) Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur
EA200701434A1 (ru) Тауриновый синтез, производство и применение в качестве лекарственного средства
MY163762A (en) Therapeutic agent for chronic renal failure
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін&#39;єкцій, застосування та спосіб приготування фармацевтичної композиції
EA200800464A1 (ru) Фармацевтическая композиция, содержащая периндоприл или его соли
TR201820411T4 (tr) Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
IL179813A0 (en) S-tenatoprazole sodium monohydrate salt and use thereof in the form of a proton pump inhibitor
EA200801137A1 (ru) Соединения для ингибирования апоптоза